- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05991336
Resultados relacionados con el crecimiento y el desarrollo en niños con talasemia beta dependiente de transfusiones después de la terapia génica
Crecimiento y desarrollo, calidad de vida relacionada con la salud de niños con beta-talasemia dependiente de transfusiones después de terapia génica
The investigate will conduct a cohort study to compare the growth and development, metabolism, lifestyle behavior, and health-related quality of life among three groups: children with transfusion-dependent β-thalassemia (TDT) who have received gene therapy, TDT children with lifelong supportive therapy and healthy children.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jun Shi, PhD
- Número de teléfono: 2223900913
- Correo electrónico: shijun@ihcams.ac.cn
Copia de seguridad de contactos de estudio
- Nombre: Jingyu Zhao, MPH
- Número de teléfono: 13752253515
- Correo electrónico: zhaojingyu@ihcams.ac.cn
Ubicaciones de estudio
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Porcelana
- Reclutamiento
- Regenerative Medicine Center
-
Contacto:
- Jun Shi, PhD
- Número de teléfono: (86)2223900913
- Correo electrónico: shijun@ihcams.ac.cn
-
Contacto:
- Jingyu Zhao, MPH
- Número de teléfono: (86)13752253515
- Correo electrónico: zhaojingyu@ihcams.ac.cn
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Participants are divided into three groups: TDT children who have received gene therapy, TDT children who have received lifelong supportive therapy, and healthy children.
Descripción
Inclusion Criteria:
Gene therapy group-inclusion
- Male or female age of 3-14 years
- TDT Children who have received gene therapy.
- Subjects who are willing and able to provide written informed consent.
Supportive therapy group-inclusion
- Gender same as the matched case
- Age similar to the matched case
- Children with β-TDT
- No history of gene therapy or allogeneic hematopoietic stem cell transplantation
- Subjects who are willing and able to provide written informed consent.
Healthy children group-inclusion
- Gender same as the matched case
- Age similar to the matched case
- Subjects who are willing and able to provide written informed consent.
Exclusion Criteria:
- Diagnosis of compound α-thalassemia
- Uncontrolled systemic fungal, bacterial, or viral infection
- History of malignant solid tumors, myeloproliferative or immunodeficiency diseases
- Diagnosed with mental illness
- Patients considered to be ineligible for the study by the investigator for reasons other than the above
Discontinuation of Study :
- Subjects who are unwilling or unable to continue participating in the study (withdrawal of informed consent) may withdraw from the study
- Subjects who received gene therapy or allogeneic hematopoietic stem cell transplantation during the study
- The subject is seriously non-compliant with the study requirements, such as missing 2 consecutive visits
- Subject lost to follow-up
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Gene therapy group
TDT Children who have received gene therapy between 3~14 years old. |
Autologous edited hematopoietic stem cell transplantation |
|
Supportive therapy group
TDT Children who received lifelong treatment with blood transfusions and iron chelation. They were selected based on the age and sex of the gene therapy group. |
|
|
Healthy children group
Healthy children were selected based on the age and sex of the gene therapy group. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Growth in pediatric subjects will be assessed by height.
Periodo de tiempo: Up to 5 years.
|
Height in meters. |
Up to 5 years.
|
|
Growth in pediatric subjects will be assessed by weight.
Periodo de tiempo: Up to 5 years.
|
Weight in kilograms. |
Up to 5 years.
|
|
Growth in pediatric subjects will be assessed by bone density.
Periodo de tiempo: Up to 5 years.
|
Bone density measurement is measured by a procedure called densitometry, performed in the radiology medicine departments of hospitals or clinics. The result is the bone mineral density in grams per unit area (g/cm2). |
Up to 5 years.
|
|
The pubertal status will be measured using by Tanner scale.
Periodo de tiempo: Up to 5 years.
|
The Tanner scale, a well-known technique used to define pubertal stage, is based on physical measurements of development based on external primary and secondary sex characteristics (from Tanner 1: pre-pubertal to Tanner 5: mature adolescent).It was developed by Marshall and Tanner while conducting a longitudinal study during the 1940s to the 1960s in England. Based on observational data, they developed separate scales for the development of external genitalia: phallus, scrotum, and testes volume in males; breasts in females; and pubic hair in both males and females. |
Up to 5 years.
|
|
Quality of life will be measured using by Pediatric Quality of Life Inventory (PedsQL) at baseline and the end of the study.
Periodo de tiempo: Up to 5 years.
|
The Pediatric Quality of Life Inventory (PedsQL) is a valid, standardized, generic, and self-reporting assessment tool to measure health-related quality of life HRQOL for pediatrics and adolescents. PedsQL contain 23-items, and consists of the following: physical functioning, emotional functioning, social functioning, and school functioning. Each item is scored on a 5-point scale, scores are linearly transformed to a 0-100 scale in which high score means better condition. |
Up to 5 years.
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- QTJC2023054
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .